|Abstract:||Somatostain analogues comprising the amino acid sequence of the formula (I): -(D/L)Trp-Lys-X.sub.1 -X.sub.2, wherein X.sub.1 is a substituted Thr, Ser, Tyr, Glu or Cys residue and X.sub.2 is an .alpha.-amino acid having an aromatic residue on the C.sub..alpha. side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t.-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys.sup.9 of the native somatostatin-14, in free form, in salt form or complexed with a detectable element have interesting pharmacological properties.|
|Inventor(s):||Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bruns; Christian (Freiburg, DE), Chandramouli; Nagarajan (Morristown, NJ), Lewis; Ian (Riehen, CH), Weckbecker; Gisbert (Biel-Benken, CH)|
|Assignee:||Novartis AG (Basle, CH)|
Patent Claim Types:|
see list of patent claims
|Compound; Process; Composition; Use;|
Field: Not categorized
Back Citations: 9th percentile
Forward Citations: 1st percentile
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9513224||Jun 29, 1995|
|United Kingdom||9600429||Jan 10, 1996|
|PCT Filed||June 28, 1996||PCT Application Number:||PCT/EP96/02840|
|PCT Publication Date:||January 16, 1997||PCT Publication Number:||WO97/01579|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.